Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5195560
Max Phase: Preclinical
Molecular Formula: C17H17N5O
Molecular Weight: 307.36
Associated Items:
ID: ALA5195560
Max Phase: Preclinical
Molecular Formula: C17H17N5O
Molecular Weight: 307.36
Associated Items:
Canonical SMILES: CC(C)Oc1cc(C#N)ccc1Nc1ncnc2ccn(C)c12
Standard InChI: InChI=1S/C17H17N5O/c1-11(2)23-15-8-12(9-18)4-5-13(15)21-17-16-14(19-10-20-17)6-7-22(16)3/h4-8,10-11H,1-3H3,(H,19,20,21)
Standard InChI Key: FOQNSWUDBARUFL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 307.36 | Molecular Weight (Monoisotopic): 307.1433 | AlogP: 3.37 | #Rotatable Bonds: 4 |
Polar Surface Area: 75.76 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.43 | CX Basic pKa: 3.96 | CX LogP: 3.26 | CX LogD: 3.26 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.80 | Np Likeness Score: -1.33 |
1. Xu W, Kannan S, Verma CS, Nacro K.. (2022) Update on the Development of MNK Inhibitors as Therapeutic Agents., 65 (2.0): [PMID:34533957] [10.1021/acs.jmedchem.1c00368] |
Source(1):